NEW YORK (Reuters Health)—Immunosuppressants and anti-TNF drugs do not appear to increase the risk of extracolonic cancers in patients with inflammatory bowel disease (IBD), researchers from Spain report. IBD patients face an increased risk of colon cancer, and some studies have suggested there might be an increased risk of extracolonic cancer. Dr. Maria Chaparro from…
Search results for: back pain
U.S. State, Local Government Lawsuits Over Opioids Face Uphill Battle
BOSTON (Reuters)—A growing number of U.S. states, counties and cities are filing lawsuits accusing drug companies of deceptively marketing opioid painkillers to downplay their addictiveness, but some lawyers say the industry’s highly regulated nature could pose a hurdle to their success. Ohio on Wednesday became the latest, and largest, state or local government to bring…
NSAIDs Increase MI Risk; Plus New Label Warnings for Canagliflozin
NSAIDs Increase Myocardial Infarction Risk According a recent meta-analysis of real-world non-steroidal anti-inflammatory drug (NSAID) use, NSAIDs may increase the risk of acute myocardial infarction (AMI). The analysis used individual patient data meta-analysis of studies from healthcare databases in Canada, Finland and the U.K. to determine the time course for risk of AMI, as well…
Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis
The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…
Optical Workings: Specialists Must Communicate to Treat Eye Disease
In an age of new medications for eye disease, rheumatologists and ophthalmologists must work together and communicate, says James Rosenbaum, MD. Teamwork and understanding how each specialty approaches the physical exam will aid patient care…
ARHP President Dr. Afton L. Hassett’s Rise from Annual Meeting Attendee to Leadership Role
Current ARHP President Afton L. Hassett, PsyD—a clinical psychologist and an associate research scientist in the Department of Anesthesiology at the University of Michigan—attended her first ACR/ARHP Annual Meeting in 1999. Dr. Hassett submitted an abstract to the meeting describing her dissertation research exploring the role of pain and depression in rheumatoid arthritis and fibromyalgia. It…
Tips for Managing Young Adult Rheumatology Patients
Often, young adults (18–23 years old) with rheumatic illness demonstrate poor adherence to treatment regimens, lack advocacy skills and have inadequate knowledge about diagnosis and treatment.1 Patients presenting at a transition clinic are typically comfortable with having their parents continue to be centrally involved with their care, but this is a time in life when…
Demand for Arthritis Care in America Outstrips Supply of Practicing Rheumatologists
May is National Arthritis Awareness Month. The ACR is committed to ensuring that arthritis and rheumatologic diseases are at the forefront of public awareness—and that better, safer treatments reach Americans in need. Fortunately, the federal government is also doing its part and has just released a major report on the national impact of arthritis. A…
The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…
Rheumatology Case Report: Immune-Related Aortitis Associated with Ipilimumab
Ipilimumab (Yervoy) is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It was the first drug to demonstrate a survival benefit in advanced melanoma and was approved by the FDA in 2011.1 By blocking the CTLA-4 receptor, ipilimumab enhances the immune response against tumors via cytotoxic T lymphocyte activation and proliferation.2 However, immunopotentiating…
- « Previous Page
- 1
- …
- 109
- 110
- 111
- 112
- 113
- …
- 155
- Next Page »